SBIR Phase I: Chiral, Carbohydrate Polyethers for Robust, High Resolution, Pharmaceutical Separations

SBIR 第一阶段：用于稳健、高分辨率药物分离的手性碳水化合物聚醚

• 批准号: 0512998
• 负责人: Alexander Gorkovenko
• 金额: --
• 依托单位: Material Methods
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0512998&HistoricalAwards=false
• 关键词: SBIR; Phase; Chiral; Carbohydrate; Polyethers

This Small Business Innovation Research Phase I project will develop a new class of carbohydrate polyethers for chiral chromatography, by starting with levoglucogan produced from starch. In nine out of the top ten selling drugs, the active ingredient is chiral. The (2-3)-polyethers are unique because they have multiple contiguous chiral centers, which can be manipulated to form desired intermediates, with unparalleled optical integrity and the highest density of functional groups of all known molecules. Drug manufacturers seek new chiral stationary phases with high and extended chiral selectivity, high loading capacity, and ability to tolerate a wide range of mobile phases. To meet this need, epoxide monomers will be synthesized and polymerized into a 100% stereo specific chiral stationary phase for liquid chromatography of enantiomers. This polyether phase will be applied to silica supports and evaluated by leading chromatography equipment manufacturers. The commercial application of this project will primarily be in the manufacture of enantiomerically pure pharmaceuticals. Further impact of the proposed work will extend to drug purification, sugar separations, selective epoxidation, and controlled polymerization for a range of bio-refinery products.

这个小型企业创新研究阶段I项目将通过从淀粉生产的左旋葡聚糖开始，开发出一种新的碳水化合物聚乙烯型聚乙an碳水化合物。在排名前十的销售药物中的九种中，活性成分是手性的。 （2-3） - 散热器是独特的，因为它们具有多个连续的手性中心，可以操纵以形成所需的中间体，具有无与伦比的光学完整性和所有已知分子的功能基团的最高密度。药物制造商寻求具有高和扩展的手性选择性，高负载能力以及耐受多种移动相的能力的新型手性固定相。为了满足这种需求，将环氧化物单体合成并聚合成100％立体声特定的手性固定相，用于映体液相色谱。该聚醚相将应用于二氧化硅支持，并通过领先的色谱设备制造商进行评估。该项目的商业应用主要是在对映体纯药物的生产中。拟议工作的进一步影响将扩展到药物纯化，糖分离，选择性环氧化和对一系列生物融资产品的受控聚合。